NCT00499928已完成1 期
An Open-Label Study to Investigate the Excretion and Metabolic Disposition of a Single, Oral Dose of [14C]-SB-751689 (a Calcium-Sensing Receptor Antagonist) in Healthy Male Subjects and Healthy Postmenopausal Female Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- The total amount of administered radioactivity recovered in excreta and the primary route of excretion over 7 days
研究概览
简要总结
This study will examine the biological fate of radioactive SB-751689 administered to healthy males and healthy postmenopausal women. Subjects will receive a single oral dose of radioactive SB-751689. Excreta and blood samples will be taken over the course of 7 days. This study will help determine the major route of elimination of SB-751689 in humans. It will also provide samples (blood, plasma, urine, and stools) for analysis of metabolites, if any.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult males of age 35 to 65 years, inclusive, or healthy ambulatory postmenopausal women defined as being amenorrheic for at least 2 years and 40 to 65 years of age, inclusive, at screening with FSH levels consistent with menopause. Healthy postmenopausal women, who are between ages 40 to 50 years, inclusive, must also have a documented history of bilateral oophorectomy (with or without hysterectomy) and be at least 6 weeks post-surgery.)
- •Non-smokers
- •Body weight > or = 50 kg and BMI within the range 19 - 32 kg/m2
- •A history of regular bowel movements
- •Capable of giving written informed consent
排除标准
- •Any clinically relevant biological or physical abnormality found or reported at screening which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study
- •QTc interval of > 450 msec at screening
- •Positive urine drug screen at screening
- •Positive urine test for alcohol at pre-dose
- •Positive for HIV at screening
- •Chronic hepatitis B and C, as evidenced by positive Hepatitis B surface antigen or Hepatitis C antibody
- •Urinary cotinine levels indicative of smoking at screening
- •History of smoking or use of nicotine containing products within one year of the study or >10 pack-year history of smoking overall
- •History of regular alcohol consumption exceeding 7 units/week for women and 14 units/week for men within 6 months of screening
- •History of drug abuse within 6 months of the study
- •Participation in a clinical study and received a drug or a new chemical entity with 30 days or 5 half-lives, or twice the duration of the biological effect of any drug prior to the first dose of the current study medication
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day
- •Subjects who have received a total body radiation dose of greater than 5.0 mSv or exposure to significant radiation in the 12 months prior to this study
- •Radiation exposure from the previous 3 year period is over 10 mSv for subjects who have been exposed to ionizing radiation above background as a result of their work with radiation as category A workers or as a result of research studies they may have been involved in. Clinical exposure will not be included
- •Condition that could interfere with the accurate assessment and recovery of radiocarbon [14C]
- •Use of prescription or nonprescription drugs including antacids, including vitamins, herbal and dietary supplements within 7 days prior to the first dose of study medication.
- •Consumption of red wine, grapefruit, grapefruit juice or grapefruit-containing products within 14 days prior to the first dose of study medication
- •Donation of blood in excess of 500 mL within 56 days prior to dosing.
- •Evidence of renal, hepatic or biliary impairment
- •History of serious gastrointestinal disease or history of a gastrointestinal surgical procedure that might affect the absorption of SB-751689
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation
- •History of clinically significant cardiovascular disease
- •History of pernicious anemia, pancreatitis, osteosarcoma or kidney stones.
- •Conditions that might alter bone metabolism, including hyperparathyroidism, hypoparathyroidism, hyperthyroidism, hypothyroidism, Paget's disease, myeloma, malabsorption, or Cushing's syndrome, and hypogonadism (for male subjects), hypocalcemia, hypercalcemia, hypophosphatemia, hypomagnesemia, hypermagnesemia, osteopetrosis, osteomalacia, and recent history of fracture or prolonged bed rest
- •Liver function tests, PTH, or CPK outside the reference range at screening
- •Males unwilling to refrain from fathering a child during the study and for 14 days after
结局指标
主要结局
The total amount of administered radioactivity recovered in excreta and the primary route of excretion over 7 days
时间窗: over 7 days
次要结局
- The amount of radioactivity associated with blood vs. plasma. The total amount radioactivity vs. SB-751689 radioactivity (metabolite vs. parent) over 7 days(over 7 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid TumorNeoplasms, MalignantNCT01063946Sanofi3
已完成
1 期
Study on Human Mass Balance of SPH3127 TabletsPrimary Mild and Moderate HypertensionNCT05593562Shanghai Pharmaceuticals Holding Co., Ltd6
已完成
1 期
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female SubjectsEpilepsyNCT03681158Sanofi5
已完成
1 期
Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male SubjectsDisorders of Sphingolipid MetabolismHealthy VolunteersNCT05238714Genzyme, a Sanofi Company6
已完成
1 期
Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205HealthyNCT04704739Galapagos NV12